» Articles » PMID: 38842565

Association of Routine Hematological Parameters with the Development of Monoclonal Gammopathies: a Case-control Study of 134,740 Patients : Resubmitted to Annals of Hematology 26 March 2024

Overview
Journal Ann Hematol
Specialty Hematology
Date 2024 Jun 6
PMID 38842565
Authors
Affiliations
Soon will be listed here.
Abstract

The diagnosis of multiple myeloma requires detection of paraproteinemia and confirmation of monoclonal bone marrow infiltration, along with signs of end-organ damage. Despite the increasing prevalence, serum paraproteinemia is not routinely measured. We examined the relationship between alterations in routine hematological parameters and the development of paraproteinemia in a case-control study. Data was retrieved from a laboratory database in the capital region of Denmark between 01/01/2012 and 31/12/2022. Patients were included if they had a test for paraproteinemia (n = 134,740) and at least one prior hematological parameter (white blood cells, hemoglobin and platelet count) with a minimum follow-up of 1 year.Between 96,999 and 103,590 patients were included in each of the three hematological groups. We found white blood cell count and the presence of paraproteinemia followed an inverse J-shaped curve, with the highest presence below 3 × 10/L and above > 9 × 10/L. The adjusted OR below and above the nadir of 4 × 10/L was 1.61 (95% CI 1.25; 2.08, p < 0.0001) and 1.03 (95% CI 1.03; 1.04, p < 0.0001). Hemoglobin levels were inversely associated the presence of paraproteinemia, with the highest association below 6 mmol/L with an OR of 1.30 (95% CI 1.28; 1.32, p < 0.0001) adjusted for age and gender. Platelet count followed a U-shaped curve with the highest association at < 100 × 10/L. The adjusted OR below and above the nadir of 250 × 10/L was 1.13 (95% CI 1.10; 1.17, p < 0.0001) and 1.10 (95% CI 1.08; 1.12, p < 0.0001) respectively. In conclusion, all three parameters showed significant association with later paraproteinemia.

References
1.
Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

2.
Rajkumar S . Multiple myeloma: Every year a new standard?. Hematol Oncol. 2019; 37 Suppl 1:62-65. PMC: 6570407. DOI: 10.1002/hon.2586. View

3.
Solmaz S, Uzun O, Sevindik O, Demirkan F, Ozcan M, Ozsan G . The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. Int J Lab Hematol. 2022; 45(1):13-19. DOI: 10.1111/ijlh.13958. View

4.
Cowan A, Green D, Kwok M, Lee S, Coffey D, Holmberg L . Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022; 327(5):464-477. DOI: 10.1001/jama.2022.0003. View

5.
Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View